Based on the sources provided, there are currently no generic versions of Kadcyla (ado-trastuzumab emtansine) available on the market. Kadcyla is a brand name medication developed by Genentech/Roche, and it is a targeted therapy used in the treatment of certain types of breast cancer.

The first source, DrugPatentWatch, provides information about the patent status of drugs. According to the information on the page for Kadcyla, the drug is still under patent protection, which means that generic versions cannot be produced and sold until the patent expires. As of now, the patent for Kadcyla is set to expire in 2031.

The second source, the Institute for Safe Medication Practices (ISMP), discusses the confusion surrounding the generic name of Kadcyla. It states that despite the availability of a generic naming convention for biologic drugs, the generic name for Kadcyla has not been established yet. This suggests that there are no generic versions of Kadcyla currently approved or available.

The third source, a BMJ article, discusses the cost-effectiveness of Kadcyla compared to other breast cancer treatments. It mentions that the high cost of Kadcyla has raised concerns, but it does not mention the availability of generic versions.

In conclusion, based on the provided sources, there are no generic versions of Kadcyla available at the moment. The drug is still under patent protection, and the generic name for Kadcyla has not been established. It is always advisable to consult with a healthcare professional or pharmacist for the most up-to-date and accurate information regarding medication availability and options.

Sources:
[1] DrugPatentWatch - https://www.drugpatentwatch.com/p/biologics/tradename/KADCYLA
[2] Institute for Safe Medication Practices - https://www.ismp.org/alerts/confusion-regarding-generic-name-her2-targeted-drug-kadcyla-ado-trastuzumab-emtansine
[3] BMJ - https://www.bmj.com/content/351/bmj.h5279